Heart rate variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome: An exploratory pilot study. — CFSMEATLAS
Heart rate variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome: An exploratory pilot study.
Windthorst, Petra, Mazurak, Nazar, Kuske, Marvin et al. · Journal of psychosomatic research · 2017 · DOI
Quick Summary
This study tested two different treatments for ME/CFS in 28 women: heart rate variability biofeedback (HRV-BF), which uses technology to help regulate breathing and nervous system activity, and graded exercise training (GET), which involves gradually increasing physical activity. Both treatments reduced fatigue, but they helped in different ways—HRV-BF appeared to help more with mood and depression, while GET seemed to improve physical functioning more.
Why It Matters
This study provides preliminary evidence that different therapeutic approaches to ME/CFS may target distinct symptom domains—mental versus physical health—suggesting that personalized or combined treatment strategies could optimize patient outcomes rather than using one-size-fits-all interventions.
Observed Findings
General fatigue improved significantly in both HRV-BF and GET groups.
Cognitive components of fatigue, mental quality of life, and depression showed significant improvement in the HRV-BF group only.
Physical quality of life improved significantly in the GET group only.
Significant between-group differences favored HRV-BF for mental quality of life and depression measures.
Benefits were sustained at 5-month follow-up.
Inferred Conclusions
Both HRV-BF and GET reduce fatigue in ME/CFS, but through potentially different mechanisms.
HRV-BF may preferentially address mental health and mood components of ME/CFS.
GET may preferentially address physical health and functioning components.
Combining both therapies might provide complementary benefits and warrants further investigation.
Remaining Questions
Would combining HRV-BF and GET produce superior outcomes compared to either treatment alone?
Do these findings generalize to men with ME/CFS, given the study included only women?
What This Study Does Not Prove
This pilot study does not establish that HRV-BF or GET is definitively effective for ME/CFS, as the small sample size (n=28) and lack of control group limit statistical power and generalizability. The findings do not clarify which treatment is superior overall, only that they may have different profiles of benefit. Long-term effectiveness beyond the 5-month follow-up period remains unknown.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only